NCT06187506View on ClinicalTrials.gov

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

January 31, 2027

Conditions
Non-muscle Invasive Bladder CancerHER-2 Protein Overexpression
Interventions
DRUG

Disitamab vedotin

2.0 mg/kg, administered intravenously every three weeks

DRUG

Bacillus Calmette Guerin Vaccine

Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER